{"frequencyBands":{"HP:0040280":[100,100],"HP:0040281":[80,99],"HP:0040282":[30,79],"HP:0040283":[5,29],"HP:0040284":[1,4],"HP:0040285":[0,0]},"page":{"anchorSlug":"glucocorticoid-remediable-aldosteronism","columns":[{"gene":"","key":"population-36f80923d658145b6b2b","label":"Aldosteronism, glucocorticoid-remediable","mondoId":"MONDO:0007080","onsetQualifier":null,"originColumnKey":"MONDO:0007080/OMIM:103900","originalViews":[{"key":"MONDO:0007080/OMIM:103900","label":"Aldosteronism, glucocorticoid-remediable","scopeLabel":"OMIM:103900","sourceScope":"This column retains the native source entry. It is not a pooled estimate for the umbrella condition."}],"recordKeys":["1008a2ddd300cb6336fc2f21aff6ee8c03df16ae5fde8bb32b88901cefb8384e","1cf6a816be9597da625778ecb0ec6d0a52a0fc5fc84b307792b9d1d4e5f5532f","476ed22126b345e512115de9cfcbfcdc211a2e42d14cc0b52d1033d0229beb09","947f33b57328e6b2ab939e934233a0e00325e450122a5e29486b97935e01fdfa","a6a7cdb758b8f7af6c47f56d5ff5f6f495dd74f4908c6e7985bff0f3740740fb","b91669978b1eed648f497e24184ad74ef7c7501cced2de6ac704204a1839db83"],"recordQualifiers":{},"scopeLabel":"OMIM:103900","sourceIds":["OMIM:103900"],"sourceScope":"This column retains the native source entry. It is not a pooled estimate for the umbrella condition."},{"gene":"","key":"population-3b228b807adeca90870b","label":"Familial hyperaldosteronism type I","mondoId":"MONDO:0007080","onsetQualifier":null,"originColumnKey":"MONDO:0007080/ORPHA:403","originalViews":[{"key":"MONDO:0007080/ORPHA:403","label":"Familial hyperaldosteronism type I","scopeLabel":"ORPHA:403","sourceScope":"This column retains the native source entry. It is not a pooled estimate for the umbrella condition."}],"recordKeys":["0f12bc959c89cb95c1fb5549a071e8e4ffe18ecaacf2ec390342e298ef4921bf","11be7a5d0a645b6a320fc988367c8586592345088f64f18a73137e40aeceb47d","3137a89d4b85d150ba9e747b2c5e1e76f39588a7b99b974e8f429b3562c941b4","352c43fa527d8122e452b18464c5b3a7656ebe1f54dceefb3cc0ce52bb13502a","3cdd4d4860374bb4a284ec256a7b5adda1ee81ced1f9673d625b8e56a013e4be","3d5549b99c714706a223c1ca0294662cf0d0ed1601c70c2449cff6f52f88e2ca","42f033cf0b29a31e88519d5b8938fc0ed56a4cf37e05f4a4489b19913fa0f45b","56149bc48756e008943665860b9085bdc869b031a1eda7918e50211486f3c487","79056b316e5c1df8bfc60b02304344b8dff1d24fff05c562b133a26161d64b8e","8d27bf5f7f3bcaab5d5d9563b93371112dfaf01af5e47362bc3fb6f9c4dac6d6","c9eed567b57558d33cbe52ac10834ba87671fd67870126557d1bd21a613e958e","ccd86620ee0d64ec0a5db090ad4681137eca38a5c2c826b3c491671842b2361b","e6311640d9a55f158ab1efbd7b1ddfcdbfe1ef50b3798a74f0599ea8c4200740","f67c23c5695b28f1910f48ef601eaabace0608b1db8bb6e712fb53dfc4bcb8a4"],"recordQualifiers":{},"scopeLabel":"ORPHA:403","sourceIds":["ORPHA:403"],"sourceScope":"This column retains the native source entry. It is not a pooled estimate for the umbrella condition."}],"comparison":{"collapseColumnsLabel":"Show default populations","defaultColumnKeys":["population-36f80923d658145b6b2b","population-3b228b807adeca90870b"],"expandColumnsLabel":"Show all source populations","intro":"Features recorded for this MONDO node. Related-node evidence is available through separately scoped comparisons.","primaryFeatureIds":["HP:0040084","HP:0000079","HP:0008221","HP:0000840","HP:0011410","HP:0003351","HP:0011739"],"scopeNoteHtml":"<p>Each column retains its native condition identifier, assessed population and annotation references. Counts are not pooled.</p>"},"coverage":{"countRecords":0,"emptyColumnKeys":[],"hpoRelease":"2026-06-23","narrativeSourceChanges":[],"records":20,"sourceGroups":{"omim":6,"orphanet":14}},"features":[{"hpoId":"HP:0040084","label":"Abnormal circulating renin concentration","primary":true},{"hpoId":"HP:0000079","label":"Abnormality of the urinary system","primary":true},{"hpoId":"HP:0008221","label":"Adrenal hyperplasia","primary":true},{"hpoId":"HP:0000840","label":"Adrenogenital syndrome","primary":true},{"hpoId":"HP:0011410","label":"Caesarean section","primary":true},{"hpoId":"HP:0003351","label":"Decreased circulating renin concentration","primary":true},{"hpoId":"HP:0011739","label":"Dexamethasone-suppressible primary hyperaldosteronism","primary":true},{"hpoId":"HP:0000421","label":"Epistaxis","primary":false},{"hpoId":"HP:0002315","label":"Headache","primary":false},{"hpoId":"HP:0000822","label":"Hypertension","primary":false},{"hpoId":"HP:0002900","label":"Hypokalemia","primary":false},{"hpoId":"HP:0000859","label":"Increased circulating aldosterone concentration","primary":false},{"hpoId":"HP:0002170","label":"Intracranial hemorrhage","primary":false},{"hpoId":"HP:0001324","label":"Muscle weakness","primary":false},{"hpoId":"HP:0002018","label":"Nausea","primary":false},{"hpoId":"HP:0001959","label":"Polydipsia","primary":false},{"hpoId":"HP:0011746","label":"Secretory adrenocortical adenoma","primary":false},{"hpoId":"HP:0000360","label":"Tinnitus","primary":false}],"ledeHtml":"Familial hyperaldosteronism type I is one of three types of familial hyperaldosteronism. Aldosterone is a hormone manufactured by the adrenal glands which helps the body retain water and sodium and excrete potassium. It is caused by a fusion of the CYP11B1 and CYP11B2 genes and is inherited in an autosomal dominant manner. These individuals are also at an increased risk for a certain type of stroke known as a hemorrhagic stroke. First-line therapy consists of a steroid such as prednisone, dexamethasone, or hydrocortisone. This will often correct the overproduction of aldosterone, lower the blood pressure, and correct the potassium levels.","mondoId":"MONDO:0007080","node":{"canonicalSlug":"glucocorticoid-remediable-aldosteronism","comparisons":[{"documentSha256":"af8816dbbfaa4a637f0aba7a052096caf62e546aab923d7802ee2ff2cbf12ee3","key":"legacy-familial-hyperaldosteronism","kind":"legacy","label":"familial hyperaldosteronism","memberIds":["MONDO:0007080","MONDO:0013359","MONDO:0014200","MONDO:0014875","MONDO:0016525"],"mondoId":"MONDO:0016525","url":"https://kcjyutqgtpgteszueluf.supabase.co/storage/v1/object/public/community-guides/learn-data/familial-hyperaldosteronism.af8816dbbfaa4a637f0aba7a052096caf62e546aab923d7802ee2ff2cbf12ee3.json"},{"documentSha256":"43a80b93c19f2aebe625ef5ea18c3cd0b59ed004ce48da183812054416e9bb9a","key":"expanded-familial-hyperaldosteronism","kind":"expanded","label":"familial hyperaldosteronism","memberIds":["MONDO:0007080","MONDO:0011576","MONDO:0013359","MONDO:0014200","MONDO:0014875","MONDO:0016525"],"mondoId":"MONDO:0016525","url":"https://kcjyutqgtpgteszueluf.supabase.co/storage/v1/object/public/community-guides/learn-data/node-comparison-43a80b93c19f2aebe625.43a80b93c19f2aebe625ef5ea18c3cd0b59ed004ce48da183812054416e9bb9a.json"}],"contexts":[],"lifecycle":"active","narrative":{"causes":[],"contentForm":"summary","independentCorroborationEstablished":false,"matchMethod":"automatic-identity-and-attribution","name":"Glucocorticoid-remediable aldosteronism","originalSourceId":"ORPHA:403","paragraphs":["Familial hyperaldosteronism type I is one of three types of familial hyperaldosteronism. Aldosterone is a hormone manufactured by the adrenal glands which helps the body retain water and sodium and excrete potassium. It is caused by a fusion of the CYP11B1 and CYP11B2 genes and is inherited in an autosomal dominant manner. These individuals are also at an increased risk for a certain type of stroke known as a hemorrhagic stroke. First-line therapy consists of a steroid such as prednisone, dexamethasone, or hydrocortisone. This will often correct the overproduction of aldosterone, lower the blood pressure, and correct the potassium levels."],"rawAttribution":"MONDO:0007080","reviewed":null,"scope":"exact","source":"GARD","sourceRelease":"2026-10-25T03:38:50Z","upstream":"GARD:0002790","url":"https://rarediseases.info.nih.gov/diseases/2790"},"ownColumnKeys":["population-36f80923d658145b6b2b","population-3b228b807adeca90870b"],"publication":"published","relationships":[{"kind":"parent","label":"familial hyperaldosteronism","mondoId":"MONDO:0016525","slug":"familial-hyperaldosteronism"}],"schemaVersion":1,"searchIndex":"/node-search/manifest.json","sourceHolds":{},"summaryHolds":[],"translation":"pending"},"records":[{"frequencyKind":"range","key":"0f12bc959c89cb95c1fb5549a071e8e4ffe18ecaacf2ec390342e298ef4921bf","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:403","disease_name":"Familial hyperaldosteronism type I","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0002315","is_excluded":false,"label":"Headache","onset_id":null,"reference":"ORPHA:403","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"1008a2ddd300cb6336fc2f21aff6ee8c03df16ae5fde8bb32b88901cefb8384e","raw":{"aspect":"P","body_system":"endocrine","disease_id":"OMIM:103900","disease_name":"Aldosteronism, glucocorticoid-remediable","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0000840","is_excluded":false,"label":"Adrenogenital syndrome","onset_id":null,"reference":"OMIM:103900","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"range","key":"11be7a5d0a645b6a320fc988367c8586592345088f64f18a73137e40aeceb47d","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"ORPHA:403","disease_name":"Familial hyperaldosteronism type I","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0001324","is_excluded":false,"label":"Muscle weakness","onset_id":null,"reference":"ORPHA:403","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"1cf6a816be9597da625778ecb0ec6d0a52a0fc5fc84b307792b9d1d4e5f5532f","raw":{"aspect":"P","body_system":"cardiovascular","disease_id":"OMIM:103900","disease_name":"Aldosteronism, glucocorticoid-remediable","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0000822","is_excluded":false,"label":"Hypertension","onset_id":null,"reference":"OMIM:103900","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"range","key":"3137a89d4b85d150ba9e747b2c5e1e76f39588a7b99b974e8f429b3562c941b4","raw":{"aspect":"P","body_system":"digestive","disease_id":"ORPHA:403","disease_name":"Familial hyperaldosteronism type I","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0002018","is_excluded":false,"label":"Nausea","onset_id":null,"reference":"ORPHA:403","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"352c43fa527d8122e452b18464c5b3a7656ebe1f54dceefb3cc0ce52bb13502a","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:403","disease_name":"Familial hyperaldosteronism type I","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0001959","is_excluded":false,"label":"Polydipsia","onset_id":null,"reference":"ORPHA:403","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"3cdd4d4860374bb4a284ec256a7b5adda1ee81ced1f9673d625b8e56a013e4be","raw":{"aspect":"P","body_system":"blood","disease_id":"ORPHA:403","disease_name":"Familial hyperaldosteronism type I","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0000421","is_excluded":false,"label":"Epistaxis","onset_id":null,"reference":"ORPHA:403","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"3d5549b99c714706a223c1ca0294662cf0d0ed1601c70c2449cff6f52f88e2ca","raw":{"aspect":"P","body_system":"endocrine","disease_id":"ORPHA:403","disease_name":"Familial hyperaldosteronism type I","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0011746","is_excluded":false,"label":"Secretory adrenocortical adenoma","onset_id":null,"reference":"ORPHA:403","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"42f033cf0b29a31e88519d5b8938fc0ed56a4cf37e05f4a4489b19913fa0f45b","raw":{"aspect":"P","body_system":"endocrine","disease_id":"ORPHA:403","disease_name":"Familial hyperaldosteronism type I","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0040084","is_excluded":false,"label":"Abnormal circulating renin concentration","onset_id":null,"reference":"ORPHA:403","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"476ed22126b345e512115de9cfcbfcdc211a2e42d14cc0b52d1033d0229beb09","raw":{"aspect":"P","body_system":"endocrine","disease_id":"OMIM:103900","disease_name":"Aldosteronism, glucocorticoid-remediable","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0003351","is_excluded":false,"label":"Decreased circulating renin concentration","onset_id":null,"reference":"OMIM:103900","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"range","key":"56149bc48756e008943665860b9085bdc869b031a1eda7918e50211486f3c487","raw":{"aspect":"P","body_system":"endocrine","disease_id":"ORPHA:403","disease_name":"Familial hyperaldosteronism type I","evidence":"TAS","frequency_raw":"HP:0040280","hpo_id":"HP:0011739","is_excluded":false,"label":"Dexamethasone-suppressible primary hyperaldosteronism","onset_id":null,"reference":"ORPHA:403","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"79056b316e5c1df8bfc60b02304344b8dff1d24fff05c562b133a26161d64b8e","raw":{"aspect":"P","body_system":"metabolic","disease_id":"ORPHA:403","disease_name":"Familial hyperaldosteronism type I","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0002900","is_excluded":false,"label":"Hypokalemia","onset_id":null,"reference":"ORPHA:403","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"8d27bf5f7f3bcaab5d5d9563b93371112dfaf01af5e47362bc3fb6f9c4dac6d6","raw":{"aspect":"P","body_system":"blood","disease_id":"ORPHA:403","disease_name":"Familial hyperaldosteronism type I","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0002170","is_excluded":false,"label":"Intracranial hemorrhage","onset_id":null,"reference":"ORPHA:403","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"reported","key":"947f33b57328e6b2ab939e934233a0e00325e450122a5e29486b97935e01fdfa","raw":{"aspect":"P","body_system":"genitourinary","disease_id":"OMIM:103900","disease_name":"Aldosteronism, glucocorticoid-remediable","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0000079","is_excluded":false,"label":"Abnormality of the urinary system","onset_id":null,"reference":"OMIM:103900","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"a6a7cdb758b8f7af6c47f56d5ff5f6f495dd74f4908c6e7985bff0f3740740fb","raw":{"aspect":"P","body_system":"endocrine","disease_id":"OMIM:103900","disease_name":"Aldosteronism, glucocorticoid-remediable","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0008221","is_excluded":false,"label":"Adrenal hyperplasia","onset_id":null,"reference":"OMIM:103900","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"b91669978b1eed648f497e24184ad74ef7c7501cced2de6ac704204a1839db83","raw":{"aspect":"P","body_system":"endocrine","disease_id":"OMIM:103900","disease_name":"Aldosteronism, glucocorticoid-remediable","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0000859","is_excluded":false,"label":"Increased circulating aldosterone concentration","onset_id":null,"reference":"OMIM:103900","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"range","key":"c9eed567b57558d33cbe52ac10834ba87671fd67870126557d1bd21a613e958e","raw":{"aspect":"P","body_system":"prenatal","disease_id":"ORPHA:403","disease_name":"Familial hyperaldosteronism type I","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0011410","is_excluded":false,"label":"Caesarean section","onset_id":null,"reference":"ORPHA:403","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"ccd86620ee0d64ec0a5db090ad4681137eca38a5c2c826b3c491671842b2361b","raw":{"aspect":"P","body_system":"cardiovascular","disease_id":"ORPHA:403","disease_name":"Familial hyperaldosteronism type I","evidence":"TAS","frequency_raw":"HP:0040280","hpo_id":"HP:0000822","is_excluded":false,"label":"Hypertension","onset_id":null,"reference":"ORPHA:403","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"e6311640d9a55f158ab1efbd7b1ddfcdbfe1ef50b3798a74f0599ea8c4200740","raw":{"aspect":"P","body_system":"ear","disease_id":"ORPHA:403","disease_name":"Familial hyperaldosteronism type I","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0000360","is_excluded":false,"label":"Tinnitus","onset_id":null,"reference":"ORPHA:403","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"f67c23c5695b28f1910f48ef601eaabace0608b1db8bb6e712fb53dfc4bcb8a4","raw":{"aspect":"P","body_system":"endocrine","disease_id":"ORPHA:403","disease_name":"Familial hyperaldosteronism type I","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0008221","is_excluded":false,"label":"Adrenal hyperplasia","onset_id":null,"reference":"ORPHA:403","source_release":"2026-06-23"},"sourceGroups":["orphanet"]}],"referenceLabels":{},"references":{"causeHtml":"<p class=\"section-source\">Source: <a href=\"https://rarediseases.info.nih.gov/diseases/2790\" rel=\"noreferrer\">GARD</a></p><p class=\"section-source\">Source: <a href=\"https://monarchinitiative.org/MONDO:0007080\" rel=\"noreferrer\">MONDO</a></p><details class=\"deep-dive\"><summary>Narrative source and scope</summary><dl><dt>Content</dt><dd>summary</dd><dt>Scope</dt><dd>exact</dd><dt>Match method</dt><dd>automatic-identity-and-attribution</dd><dt>Upstream attribution</dt><dd>GARD:0002790</dd></dl></details>","identityNote":"MONDO identifies this node. Native source populations, annotation references and qualified comparison views retain their original scopes.","importantHtml":""},"sections":[{"bodyHtml":"<p>Familial hyperaldosteronism type I is one of three types of familial hyperaldosteronism. Aldosterone is a hormone manufactured by the adrenal glands which helps the body retain water and sodium and excrete potassium. It is caused by a fusion of the CYP11B1 and CYP11B2 genes and is inherited in an autosomal dominant manner. These individuals are also at an increased risk for a certain type of stroke known as a hemorrhagic stroke. First-line therapy consists of a steroid such as prednisone, dexamethasone, or hydrocortisone. This will often correct the overproduction of aldosterone, lower the blood pressure, and correct the potassium levels.</p><p class=\"section-source\">Source: <a href=\"https://rarediseases.info.nih.gov/diseases/2790\" rel=\"noreferrer\">GARD</a></p>","key":"overview","title":"Overview"}],"sharedSources":[],"slug":"glucocorticoid-remediable-aldosteronism","sourceDocuments":[{"name":"GARD: Glucocorticoid-remediable aldosteronism","reviewed":null,"source_release":"2026-10-25T03:38:50Z","url":"https://rarediseases.info.nih.gov/diseases/2790"},{"name":"MONDO: glucocorticoid-remediable aldosteronism","reviewed":null,"source_release":"releases/2026-10-06","url":"https://monarchinitiative.org/MONDO:0007080"}],"sourceNote":"","synonyms":["aldosteronism, glucocorticoid-remediable","dexamethasone sensitive hypertension","dexamethasone-sensitive hypertension","familial hyperaldosteronism type 1","FH-I","FH1","glucocorticoid sensitive hypertension","glucocorticoid-remediable aldosteronism","glucocorticoid-sensitive hypertension","GRA","HALD1","hyperaldosteronism, familial type 1"],"takeawayHtml":"","title":"glucocorticoid-remediable aldosteronism"},"schemaVersion":1}
